GlassScriptPhysician profile
Nicholas J Rowder
NPI 1942230164
$668.32
in general payments reported to CMS, 2019-2025
12 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.58 · 2022: $30.63 · 2023: $133 · 2024: $97.92 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $105.95 | 2025 | |
| Amgen INC. | $98.70 | 2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $92.46 | 2024-2025 | |
| Glaxosmithkline, LLC. | $73.90 | 2022-2024 | Benlysta, Nucala, Jesduvroq |
| Aurinia Pharma U.S., INC. | $52.73 | 2023-2025 | Lupkynis |
| Bard Peripheral Vascular, INC. | $51.81 | 2021-2023 | Covera |
| Lilly USA, LLC | $47.90 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $44.65 | 2022-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $29.87 | 2025 | |
| Calliditas Therapeutics US INC. | $28.04 | 2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $23.37 | 2023 | Velphoro |
| Mallinckrodt Hospital Products INC. | $18.94 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Rowder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.